ImmuPharma reports interim loss amid breakthroughs in autoimmune drug platform
The Group posted a loss of £1.8 million, up from £0.4 million in the same period last year LONDON: ImmuPharma PLC (LSE:IMM), a specialist in drug discovery and development, reported a widened interim loss for the six months ended June…